Coland, ScinoPharm To Partner For Cancer Drugs In Mainland China
This article was originally published in PharmAsia News
Executive Summary
Hong Kong's Coland Holdings and ScinoPharm Taiwan plan to collaborate with a yet-to-be-chosen third company in developing generic cancer drugs on the China mainland.